Selective Bacterial Nitric Oxide Synthase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods face challenges in developing selective inhibitors for bacterial nitric oxide synthase (bNOS) due to structural similarities with mammalian NOS isoforms, particularly in targeting the pterin-binding site, which is essential for achieving isoform specificity and avoiding interference with critical mammalian NO functions.
Innovation Solution
The development of compounds that selectively inhibit bacterial nitric oxide synthases by targeting the pterin-binding site, utilizing specific chemical moieties and linker compositions to form stable interactions with the active site and pterin site, thereby achieving selective inhibition over mammalian NOS isoforms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhibitors target the pterin-binding site to achieve selective inhibition of bNOS, then isoform specificity is improved, but the structural similarity between bNOS and mNOS makes selective inhibition difficult
Solution Approach 1:
The patent applies local quality by focusing inhibition on the pterin-binding site, a specific local region of the NOS enzyme. The compounds are designed to selectively interact with the pterin cofactor binding pocket, which has distinct structural features in bNOS compared to mNOS isoforms. This localized targeting approach allows the inhibitor to exploit subtle structural differences at the pterin site while ignoring the overall structural similarity between bacterial and mammalian NOS enzymes.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of compounds to optimize their binding affinity and selectivity for the bNOS pterin site. The compounds contain specific chemical moieties and linker compositions that are tuned to match the structural parameters of the bNOS pterin-binding site, creating optimal steric and electronic complementarity. This parameter optimization enables selective inhibition despite the general structural conservation between bNOS and mNOS.
2Reliability
If compounds are designed to selectively inhibit bNOS over mNOS isoforms, then therapeutic efficacy against antibiotic-resistant infections is improved, but the risk of interfering with critical mammalian NO functions increases
Solution Approach 1:
The patent uses the pterin cofactor as an intermediary element to achieve selective inhibition. The compounds are designed to displace or compete with the pterin cofactor at the bNOS active site, thereby indirectly inhibiting enzyme activity. This intermediary approach allows selective targeting because the pterin-binding site has sufficient structural divergence between bNOS and mNOS isoforms to permit discriminative binding, while the overall enzyme function remains similar.
Solution Approach 2:
The patent employs structure-based drug design by creating compounds that copy or mimic the pterin cofactor structure. The inhibitors are designed to resemble the natural pterin substrate, allowing them to bind to the same site and compete for occupancy. This copying strategy enables selective inhibition of bNOS by exploiting the specific structural features of the bacterial enzyme's pterin-binding site, which differ from the mammalian isoforms.
Data Source
AI summary
Disclosed are compounds that are shown to inhibit the biological activity of nitric oxide synthases (NOSs). Also disclosed are pharmaceutical compositions comprising the compounds, and methods of using the compounds and pharmaceutical compositions for treating a subject in need thereof. Because the disclosed compounds are shown to inhibit the activity of nitric oxide synthases (NOSs), the disclosed compounds and pharmaceutical compositions may be utilized in methods for treating a subject having or at risk for developing a disease or disorder that is associated with NOS activity.